U.S. Patent 8131371 was awarded to Ardian, Inc. on 2012-03-06 and describes a “Methods and apparatus for monopolar renal neuromodulation.” This patent has been cited 243 times by other U.S. patents which places it in the top 500 cited patents since 2010 according to our law firm research, and makes it of the most innovative medical technology patents in the field of instruments. The abstract states:

Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally. Link: U.S. Patent 8131371

This patent was originally filed on 2006-04-13 which gives it a processing time of 2154 days, compared to an average processing time of 1788 in the field. Ardian, Inc. has 29 total patents. The first named inventor is Hanson S. Gifford, III of , NY. The primary examiner was Mark W Bockelman.

Select Patents monitors top medical technology patents and instruments patents which have been allowed and granted worldwide. If you would like legal advice regarding a patent or would like to file a patent go to https://selectpatents.wpengine.com/contact/